Stephens & Co. Reiterates Overweight on Elevance Health, Maintains $615 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Scott Fidel has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $615.
September 05, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stephens & Co. has reiterated its Overweight rating on Elevance Health, maintaining a price target of $615, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and a maintained price target of $615 by Stephens & Co. suggests a positive outlook on Elevance Health's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100